Welcome from NHRC

KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer

Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients

Adjuvant radiotherapy has no benefit following radical prostatectomy

Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC

Where do we stand with mCRPC?

PARPi combinations to treat patients with mCRPC

Selpercatinib benefit, with or without pembro, in first-line advanced RET fusion-positive NSCLC

Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer

Active surveillance for oesophageal cancer shows improved HRQoL compared to standard surgery

Sotorasib and panitumumab demonstrate clinically meaningful benefit in KRAS G12C-mutated metastatic colorectal cancer 

Datopotamab deruxtecan extends PFS vs chemo for HR+/HER2- breast cancer